APPLICATION
Application Note
The peptide is used for blocking the antibody activity of anti-IL-21R (cat. no GTX22067). It usually blocks the antibody activity completely in Western blot by incubating the peptide with equal volume of antibody for 30 min at 37ºC.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Interleukin 21 Receptor , Cd360 , Imd56 , Nilr , Il21R
Background
A novel cytokine related to IL-2 and IL-15 was recently identified and designated IL-21. The receptor for IL-21 (IL-21R, also termed NILR for novel Interleukin receptor) is a new member of the class I cytokine receptor family. IL-21R forms a complex with the common cytokine receptor g chain, gc, and mediates IL-21 signaling. Both IL-21R and the gc are necessary for IL-21 function. IL-21 and its receptor activate the JAK-STAT signaling pathway. IL-21R is expressed in spleen, thymus, natural killer (NK), T and B cell lines. IL-21 plays a role in the proliferation and maturation of NK, B and T cell populations.
Research Area
REFERENCE
There are currently no references for IL21 Receptor peptide (GTX26226). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for IL21 Receptor peptide (GTX26226). Be the first to share your experience with this product.